Specifically, in a study of four patients with melanoma whose disease initially responded to anti-PD-1 treatment but relapsed months to years later, two patients had homozygous loss-of-function mutations in their Janus kinase 1 (JAK1) or JAK2 genes (107). The gene discussed is PDCD1; the disease is melanoma.